Nemucore Medical Innovations, Inc. Awarded SBIR Grant for Development Of Novel Multifunctional Nanoemulsion For Imaging And Therapy Of Ovarian Cancer
Nemucore Medical Innovations, Inc. (NMI), announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the National Cancer Institute (NCI). The NMI-300 program assesses and validates the imaging, targeting
Wellesley (I-Newswire) November 16, 2010 - Nemucore Medical Innovations, Inc. (NMI), announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the National Cancer Institute (NCI). The NMI-300 program assesses and validates the imaging, targeting, cytotoxicity and pharmacokinetics of novel multifunctional nanoemulsions containing lipophilic platinum-derivatives alone or in combination with the pro-apoptopic molecules.
Today 70% of patients with advanced ovarian cancer will achieve clinically complete remission with first line treatments of carboplatin and paclitaxel. Unfortunately a majority these patients are destined to relapse and eventually die of disease due to a persistence of chemoresistant cells which metastasize throughout the body. Our overarching strategy addresses the major failures of the first line therapy and diagnostics by using multifunctional nanoemulsions to target, image, and eradicate chemosensitive and chemoresistant tumor cells. This SBIR program will extend prior rodent studies and move the technology one step closer to clinical utility.
NMI has created a consortium of partners that will support the program, including Northeastern University, and The Nanotechnology Characterization Laboratory.
NMI President and CEO Dr. Tim Coleman states that this work will make an impact on patient care, "Nanomedicine development is at its nascent stage, and the focus of NMI's work is on developing novel concepts into life saving products."
Mansoor Amiji, Distinguished Professor and Chair, Department of Pharmaceutical Sciences, at Northeastern University's School of Pharmacy, Bouve College of Health Sciences, and NMI co-founder , developed the initial technology that has been licensed by NMI . Prof Amiji said, "The improved bioavailability of these nanonemulsions will significantly extend the therapeutic impact to chemoresistant ovarian cancer cells. Advancing translation research of these safe and effective multifunctional nanoemulsions is urgently needed to create products with enhanced clinical utility."
About Nemucore Medical Innovations
Nemucore Medical Innovations, Inc. is dedicated to the development and commercialization of life-sav More..ing nanomedicines for the treatment of MDR cancers. We accomplish this objective by conceiving, testing and manufacturing nanomedicines, applying our proprietary nanoformulation technologies to drugs that need improved delivery solutions. NMI was founded in 2008 and is based in Worcester and Wellesley.Less..
Nemucore Medical Innovations
33 Kirkland Circle
Phone : (617) 285-3561
Published in:Science and Research
Published On:November 16, 2010
Print Release:Print Release
If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.
The Genome Registry Is Making Genes Sexy On Multiple Platforms
Mark F. Kalita Publishes "Light Event" in Which the 'Light Formula' for the Human Being Is Announced
NanoHybrids Launches Its First Product Line of Imaging Contrast Agents
Ready For Take-Off: Launch of New Data Model Boosts Space Science
Free GCP Course Has Been Released